SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer

Inclusion Criteria: 1. Age 18\~75 years old, both male and female; 2. Histologically or cytologically confirmed unresectable locally advanced, or recurrent/metastatic biliary tract adenocarcinoma (including gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma); 3. Has not received prior systemic anti-tumor therapy; 4. At least one measurable lesion based on RECIST v1.1 criteria; 5. ECOG PS score: 0-1 points; 6. Expected survival period ≥ 3 months; 7. Adequate organ function; 8. Must take one medically approved contraceptive measure; 9. Patients voluntarily joined the study and signed informed consent. Exclusion Criteria: 1. history or concurrently has other solid tumor; 2. Patients with liver tumor burden greater than 50% of total liver volume; 3. History of previous hepatic encephalopathy; 4. Patients with biliary obstruction ， at risk of biliary tract infection; 5. Patients with undergone major surgical treatment within 4 weeks before randomization; 6. Patients with any active, known or suspected autoimmune disorder; 7. Patients with active pulmonary tuberculosis; 8. Patients with known history of HIV or active hepatitis; 9. Untreated central nervous system metastasis; 10. Pleural or peritoneal effusion with clinical symptoms; 11. Patients with poorly controlled cardiac clinical symptoms or disease; 12. Patients with abnormal coagulation function and bleeding tendency; 13. Known allergic reaction to Adalimumab or other monoclonal antibodies, or to the trial drug; 14. Patients with other potential factors that may affect the study results.